Identifying prognostic and predictive value of mutations associated with clinical outcomes in first line (1L) patients with advanced or metastatic non–small cell lung cancer (aNSCLC).

Authors

Diego Perez Parente

Lung Cancer Squad, Roche Farma, Madrid, Spain

Diego Perez Parente , Manuel Cobo-Dols , Haroon Hasan , Sara Olson , Navdeep Pal , Samantha Wilkinson , Beatriz La Orden Tévar , Mar Pérez Fernández , Mariano Provencio-Pulla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.

First Author: Hina Khan

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.

First Author: Kathryn C. Arbour

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

First Author: Luis G. Paz-Ares

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Molecular characterization of long-term and short-term survivors of advanced pancreatic ductal adenocarcinoma.

First Author: Jesús Fuentes Antrás